HC Wainwright Has Lowered Expectations for BioLineRx (NASDAQ:BLRX) Stock Price

BioLineRx (NASDAQ:BLRX) had its price objective cut by HC Wainwright from $21.00 to $9.00 in a research note published on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.14) EPS and FY2025 earnings at ($0.13) EPS.

Separately, StockNews.com began coverage on shares of BioLineRx in a research note on Sunday, November 24th. They set a “hold” rating for the company.

BioLineRx Stock Performance

BLRX stock opened at $0.29 on Monday. BioLineRx has a 1 year low of $0.25 and a 1 year high of $1.89. The stock has a market capitalization of $22.94 million, a price-to-earnings ratio of -1.30 and a beta of 1.48. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The stock’s fifty day moving average is $0.47 and its two-hundred day moving average is $0.60.

Institutional Investors Weigh In On BioLineRx

Several institutional investors have recently bought and sold shares of BLRX. CVI Holdings LLC acquired a new position in BioLineRx during the 2nd quarter valued at about $462,000. Atria Investments Inc lifted its stake in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares during the period. Finally, PVG Asset Management Corp bought a new position in shares of BioLineRx in the second quarter valued at approximately $70,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.